Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

Canadian Journal of Gastroenterology

Volumn 20, Issue 10, 2006, Pages 661-663

  Leung, Yvette ^a   Urbanski, Stefan J ^b   Schindel, Lynn ^a   Myers, Robert P ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Viral Hepatitis Clinic   (Canada)

Author keywords

Adverse effects; Colitis; Drug toxicity; Hepatitis C; Interferon; Ischemia; Pegylated interferon alpha; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ABDOMINAL DISCOMFORT; ADULT; ALCOHOL ABUSE; ARTICLE; CASE REPORT; COCAINE DEPENDENCE; DEPRESSION; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; HEPATITIS C; HUMAN; INSOMNIA; ISCHEMIC COLITIS; LABORATORY DIAGNOSIS; LIVER BIOPSY; MALE; NOSE RECONSTRUCTION; PRIORITY JOURNAL; RISK FACTOR; SIGMOIDOSCOPY; TREATMENT DURATION;

EID: 33751224733     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/687836     Document Type: Article

References (34)

1. Davis GL. Treatment of chronic hepatitis C. BMJ 2001;323:1141-2.
2. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-7.
3. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996;23-366-71.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
5. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
7. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003;124:1711-9.
8. Sprenger R, Sagmeister M, Offner F. Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis. Gut 2005;54:438-9.
9. Mavrogiannis C, Papanikolaou IS, Elefsiniotis IS, Psilopoulos DI, Karameris A, Karvountzis G. Ulcerative colitis associated with interferon treatment for chronic hepatitis C. J Hepatol 2001;34:964-5.
10. Tada H, Saitoh S, Nakagawa Y, et al. Ischemic, colitis during interferon-alpha treatment for chronic active hepatitis C. J Gastroenterol 1996;31:582-4.
11. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
12. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20:15-20.
13. Mitsudo S, Brandt LJ. Pathology of intestinal ischemia. Surg Clin North Am 1992;72:43-63.
14. Burns BJ, Brandt LJ. Intestinal ischemia. Gastroenterol Clin North Am 2003;32:1127-43.
15. Brandt LJ, Boley SJ. AGA technical review on intestinal ischemia. American Gastrointestinal Association. Gastroenterology 2000;118:954-68.
16. Mateo I, Pinedo A, Gomez-Beldarrain M, Basterretxea JM, Garcia-Monco JC. Recurrent stroke associated with cannabis use. J Neurol Neurosurg Psychiatry 2005;76:435-7.
17. Zachariah SB. Stroke after heavy marijuana smoking. Stroke 1991;22:406-9.
18. Lawson TM, Rees A. Stroke and transient ischemic attacks in association with substance abuse in a young man. Postgrad Med J 1996;72:692-3.
19. Kosior DA, Filipiak KJ, Stolarz P, Opolski G. Paroxysmal atrial fibrillation following marijuana intoxication: A two-case report of possible association. Int J Cardiol 2001;78:183-4.
20. Bachs L, Morland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001;124:200-3.
21. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001;103:2805-9.
22. Disdier P, Granel B, Serratrice J, et al. Cannabis arteritis revisited - ten new case reports. Angiology 2001;52:1-5.
23. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004;11:243-50.
24. Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 1995;113:1041-4.
25. Schapira D, Nahir AM, Hadad N. Interferon-induced Raynaud's syndrome. Semin Arthritis Rheum 2002;32:157-62.
26. Tanaka H, Yamakado T, Emi Y, Nabeshima K, Itoh S, Nakano T. Interferon-induced coronary vasospasm. A case history. Angiology 1995;46:1139-43.
27. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991;99:557-61.
28. Molineux G. Pegylation: Engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003;23:3S-8S.
29. Sparano JA, Dutcher JP, Kaleya R, et al. Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. Cancer 1991;68:1538-44.
30. Tilg H. New insights into the mechanisms of interferon alfa: An immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997;112:1017-21.
31. Zeidman A, Dicker D, Mittelman M. Interferon-induced vasospasm in chronic myeloid leukaemia. Acta Haematol 1998;100:94-6.
32. Cnudde F, Gharakhanian S, Luboinski J, Dry J, Rozenbaum W. Cutaneous local necrosis following interferon injections. Int J Dermatol 1991;30:147.
33. Blaheta RA, Scholz M, Hailer NP, Bereiter-Hahn J, Encke A, Markus BH. Adhesion and penetration properties of human lymphocytes acting on allogeneic vascular endothelial cells. Immunology 1994;81:538-45.
34. Ronnblom LE, Alm GV, Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 1991;30:537-40.